Courts Tech CEO convicted in COVID-19, allergy test fraud case - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
September 3, 2022 Newswires
Share
Share
Post
Email

Courts Tech CEO convicted in COVID-19, allergy test fraud case

Monterey County Herald (CA)

SAN FRANCISCO >> A Silicon Valley executive who prosecutors said lied to investors about inventing technology that tested for allergies and COVID-19 using only a few drops of blood and charged up to $10,000 per allergy test was found guilty of health care fraud, authorities announced Friday.

A federal jury on Thursday convicted Mark Schena, of Los Altos, of paying bribes to doctors and defrauding the government after his company billed Medicare $77 million for fraudulent coronavirus and allergy tests, the U.S. Department of Justice said in a statement.

Schena, 59, claimed his Sunnyvale, California-based company, Arrayit Corp., had the only laboratory in the world that offered “revolutionary microarray technology” that allowed it to test for allergies and the coronavirus with the same finger-stick test kit, prosecutors said.

Alexandra Block, an attorney representing Schena, did not immediately return a phone message Friday seeking comment.

The case against Schena shared similarities with a more prominent legal saga surrounding former Silicon Valley star Elizabeth Holmes, who dropped out of Stanford University in 2003 to found a company called Theranos that she pledged would revolutionize health care with a technology that could scan for hundreds of diseases and other issues with just a few drops of blood, too.

As Theranos’ CEO, Holmes went on to raise nearly $1 billion from successful business leaders such as Oracle founder Larry Ellison and media mogul Rupert Murdoch. Holmes, now 38, was convicted on four felony counts of investor fraud in January following a nearly four-month trial in the same San Jose, California, courtroom where Schena’s trial was held.

Holmes faces up to 20 years in prison at her Oct. 17 sentencing.

The two cases intersected briefly Thursday morning when the jury deliberating in Schena’s trial sent three questions to the judge, triggering an hourlong delay in a hearing about Holmes’ unsuccessful attempt to overturn the jury’s conviction of her.

Prosecutors said that after Arrayit’s allergy testing business declined in 2020 amid the pandemic, Schena falsely announced that his company had a test for COVID-19 based on its blood testing technology before even developing it. After his company submitted it to the Food and Drug Administration, he did not disclose that the FDA concluded the test was not accurate enough to be authorized for emergency use, prosecutors said.

“Schena orchestrated a deceptive marketing scheme that falsely claimed that Dr. Anthony Fauci and other prominent government officials had mandated testing for COVID-19 and allergies at the same time and required that patients receiving the Arrayit COVID-19 test also be tested for allergies,” they said.

Arrayit’s stock price more than doubled by mid-March 2020, even as the stock market was crashing, according to court documents.

Schena also failed to release Arrayit’s SEC-required financial disclosures and concealed that Arrayit was on the verge of bankruptcy, prosecutors said. The case against him was the first criminal securities fraud prosecution related to the COVID-19 pandemic, they said.

Before the pandemic, from 2018 through February 2020, Schena and other employees paid bribes to recruiters and doctors to run an allergy screening test for 120 allergens ranging from stinging insects to food allergens on every patient whether they were needed or not, authorities said.

“Arrayit billed more per patient to Medicare for blood-based allergy testing than any other laboratory in the United States and billed some commercial insurers over $10,000 per test,” they said.

Schena was convicted of one count of conspiracy to commit health care fraud and conspiracy to commit wire fraud, two counts of health care fraud, one count of conspiracy to pay kickbacks, two counts of payment of kickbacks, and three counts of securities fraud.

He faces up to 20 years in prison at a Jan. 30 sentencing.

Older

Equestrian Insurance Market to Witness Huge Growth by 2027: Madden Equine Insurance, AXA, Markel

Newer

Bloodstock Insurance Market Outlook 2022: Big Things Are Happening

Advisor News

  • I started using AI, but what now?
  • How to support an entrepreneur client with multiple businesses
  • Could a narrower focus help grow your practice?
  • U.S. debt hits $40 trillion: how to support concerned clients
  • Flourish brings private-bank-like cash solution to MassMutual’s network
More Advisor News

Annuity News

  • MassMutual Expands Lending Options With New Secured Credit Line
  • Corebridge Financial Introduces Progressive Trigger, a First-of-Its-Kind Index Annuity Strategy Designed to Turn Missed Years into Future Opportunity
  • Insurer proposes $1.1M deal to resolve CA teachers’ annuity fee lawsuit
  • IMOs get frustrated with slow carrier adoption of faster technology
  • New class-action lawsuit targets Delaware Life over annuity disclosures
More Annuity News

Health/Employee Benefits News

  • Terry Savage: Questions answered on open enrollment
  • New Jersey residents will see Affordable Care Act premiums jump 20% on average for 2027 health insurance
  • Health insurance hits municipal budgets, taxpayers hard
  • Minnesota seniors face tough choices for health plans
  • Recent Findings from New York University (NYU) Langone Health Provide New Insights into Managed Care (State Medicaid Body Mass Index Requirements for Solid Organ Transplant Coverage: A 50-State Policy Review): Managed Care
More Health/Employee Benefits News

Life Insurance News

  • Virginia orders Atlantic Coast Life to halt new business Nov. 1
  • AM Best Affirms Credit Ratings of China Taiping Insurance (Singapore) Pte. Ltd.
  • AM Best Upgrades Credit Ratings of Fidelity Life Association, A Legal Reserve Life Insurance Company; Affirms Credit Ratings of Industrial Alliance Insurance and Financial Services Inc. and Its Life/Health Subsidiaries
  • 777 Partners founder pleads guilty to $500 million fraud scheme
  • AM Best Affirms Credit Ratings of Luen Fung Hang Insurance Company Limited
Sponsor
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
  • Lauren Sinnott Named to Ragan’s Top Women in Marketing Awards, Class of 2026 
  • Classic Car Insurer OpenRoad Insurance Expands to 40 U.S. States in Two Years
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.